Guanylyl cyclase C as a Diagnostic and Therapeutic Target in Colorectal Cancer

Authors

Adi Caspi, Thomas Jefferson UniversityFollow
Ariana A. Entezari, Thomas Jefferson UniversityFollow
Madison Crutcher, Thomas Jefferson UniversityFollow
Adam E. Snook, Thomas Jefferson UniversityFollow
Scott A. Waldman, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-26-2022

Comments

This article is the authors' final version prior to publication in Personalized Medicine, Volume 19, Issue 5, August 2022.

The published version is available at https://doi.org/10.2217/pme-2022-0026. Copyright © Future Medicine Ltd.

Abstract

Colorectal cancer remains a major cause of mortality in the USA, despite advances in prevention and screening. Existing therapies focus primarily on generic treatment such as surgical intervention and chemotherapy, depending on disease severity. As personalized medicine and targeted molecular oncology continue to develop as promising treatment avenues, there has emerged a need for effective targets and biomarkers of colorectal cancer. The transmembrane receptor guanylyl cyclase C (GUCY2C) regulates intestinal homeostasis and has emerged as a tumor suppressor. Further, it is universally expressed in advanced metastatic colorectal tumors, as well as other cancer types that arise through intestinal metaplasia. In this context, GUCY2C satisfies many characteristics of a compelling target and biomarker for gastrointestinal malignancies.

Recommended Citation

Caspi, Adi; Entezari, Ariana A.; Crutcher, Madison; Snook, Adam E.; and Waldman, Scott A., "Guanylyl cyclase C as a Diagnostic and Therapeutic Target in Colorectal Cancer" (2022). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 149.
https://jdc.jefferson.edu/petfp/149

PubMed ID

35920071

Language

English